B-type natriuretic peptide and glycaemia: an emerging cardiometabolic pathway?

Diabetologia. 2012 May;55(5):1240-3. doi: 10.1007/s00125-012-2515-3. Epub 2012 Mar 8.

Abstract

There is emerging evidence of cross-talk between the myocardium and systemic metabolic pathways. In particular, there is interest in the potential metabolic effects of A-type and B-type natriuretic peptides (ANP and BNP), produced in the myocardial tissue in response to ventricular stretch and cardiac overload. This commentary provides an overview of the evidence that natriuretic peptides promote lipolysis and enhance adiponectin production. In addition, we review new and existing evidence that BNP may directly improve glucose control, or else lower glucose indirectly via enhanced capillary permeability or greater renal excretion. Further investigation of the links between natriuretic peptide and glycaemia would seem important given the potential to reveal novel mechanisms to treat diabetes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Glucose Tolerance Test*
  • Humans
  • Male
  • Natriuretic Agents / administration & dosage*
  • Natriuretic Peptide, Brain / administration & dosage*

Substances

  • Natriuretic Agents
  • Natriuretic Peptide, Brain